Gritstone bio, Inc. – NASDAQ:GRTS

Add to watchlist

Market closed

Open in about 14 hours

-19.01%

month

-36.89%

quarter

-73.36%

year

Market Cap	3.80M
Enterprise value	259.39M

P/E	-2.31
EV/Sales	13.00
EV/EBITDA	-2.31
Price/Sales	13.76
Price/Book	1.60
PEG ratio	0.05
EPS	-1.3

Revenue	2.04M
EBITDA	-149.62M
Income	-144.89M
Revenue Q/Q	-90.95%
Revenue Y/Y	-59.67%

Profit margin	-600.09%
Oper. margin	-603.8%
Gross margin	0%
EBIT margin	-603.8%
EBITDA margin	-7323.74%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Gritstone bio, Inc. (NASDAQ:GRTS): Profit margin
Jun 2023	400K	-35.25M	-8814%
Sep 2023	1.56M	-38.43M	-2455.85%
Dec 2023	29K	-30.81M	-106268.97%
Mar 2024	49K	-40.38M	-82418.37%

Gritstone bio Financials Estimate

Q Y

Gritstone bio, Inc. (NASDAQ:GRTS): Analyst Estimates
Mar 2024	49K	-40.38M	-82418.37%
Sep 2025	50.5M	-21.46M	-42.51%
Oct 2025	26.15M	-23.08M	-88.28%
Dec 2025	18.65M	-23.67M	-126.96%

Analysts Price target
Financials & Ratios estimates

Gritstone bio, Inc. (NASDAQ:GRTS): Debt to assets
Jun 2023	222623000	113.05M	50.78%
Sep 2023	187217000	113.23M	60.48%
Dec 2023	177769000	125.91M	70.83%
Mar 2024	137212000	123.24M	89.82%

Gritstone bio, Inc. (NASDAQ:GRTS): Cash Flow
Jun 2023	-30.96M	24.59M	1.01M
Sep 2023	-31.08M	18.28M	-264K
Dec 2023	-34.37M	38.29M	30.58M
Mar 2024	-33.56M	12.30M	-379K

Gritstone bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Gritstone bio, Inc. (NASDAQ:GRTS): Employee count
Aug 2023	233
Sep 2023	233
Oct 2023	233
Nov 2023	233
Dec 2023	233
Jan 2024	233
Feb 2024	233
Mar 2024	231
Apr 2024	231
May 2024	231
Jun 2024	231
Jul 2024	231

Gritstone bio
Hedge Funds Holdings Q1 2022

51.56% -11.82%

of GRTS is owned by hedge funds

113 -2

hedge funds hold GRTS stock

39.94M -9.15M

shares is hold by hedge funds

GRTS hedge funds holdings changes

Gritstone bio, Inc. (NASDAQ:GRTS): Insider trades (number of shares)
Period	Buy	Sel
May 2024	0	74769
Dec 2024	0	12000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Dec 2024	ECONOMIDES VASSILIKI officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Stock	12,000	$0.02	$180
Sale	16 May 2024	ALLEN ANDREW R director, officer: PRESIDENT AND CEO director, officer: PRESIDENT AN..	Common Stock	24,263	$0.75	$18,149
Sale	16 May 2024	JONES ERIN officer: EVP, CHIEF OPERATING OFFICER officer: EVP, CHIEF OPERATING O..	Common Stock	13,749	$0.75	$10,284
Sale	16 May 2024	JOOSS KARIN officer: SEE REMARKS officer: SEE REMARKS	Common Stock	13,749	$0.75	$10,284
Sale	16 May 2024	HAWRYLUK MATTHEW officer: EVP, CHIEF BUSINESS OFFICER officer: EVP, CHIEF BUSINESS OF..	Common Stock	9,259	$0.75	$6,926
Sale	16 May 2024	ECONOMIDES VASSILIKI officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Stock	13,749	$0.75	$10,284
Purchase	23 May 2023	ECONOMIDES VASSILIKI officer: See Remarks officer: See Remarks	Common Stock	12,000	$1.9	$22,824
Option	1 Dec 2021	JONES ERIN officer: Chief Operating Officer officer: Chief Operating Officer	Stock Option (Right to Buy)	1,000	$0.35	$345
Sale	1 Dec 2021	JONES ERIN officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	1,000	$13.01	$13,010
Option	1 Dec 2021	JONES ERIN officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	1,000	$0.35	$345

Gritstone bio
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q1 2023 11 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 9 Mar 2023	Q4 2022 Earnings Call Transcript
Q2 2022 6 Aug 2022	Q2 2022 Earnings Call Transcript

GRTS earnings call transcripts

Gritstone bio
Executives

Insider	Age	Since	Compensation
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. (1967) Co-Founder, Pres, Chief Executive Officer & Director	58		$873,680
Mr. Erin E. Jones M.S. (1972) Chief Operating Officer	53		$537,380

Gritstone bio
Latest News

Thursday, 10 October 2024
05:50	Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure	businesswire.com
Tuesday, 1 October 2024
13:55	Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'	benzinga.com
Monday, 30 September 2024
16:05	Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer	globenewswire.com
Thursday, 15 August 2024
19:45	Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm	accesswire.com
Tuesday, 13 August 2024
18:30	Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
16:05	Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates	globenewswire.com
Wednesday, 7 August 2024
21:00	GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	globenewswire.com
19:50	Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm	accesswire.com
Tuesday, 6 August 2024
17:50	Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights – GRTS	accesswire.com
17:30	GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm	accesswire.com
15:45	Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - GRTS	accesswire.com
10:15	GRTS LAWSUIT ALERT: Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	accesswire.com
10:00	GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm	prnewswire.com
07:30	Gritstone bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS	accesswire.com
05:45	Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS	prnewswire.com
05:45	Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS	prnewswire.com
05:10	August 6, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - GRTS	accesswire.com
05:00	FINAL GRTS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Gritstone bio, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com
Monday, 5 August 2024
15:40	Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Gritstone bio, Inc.(GRTS) Shareholders	accesswire.com
13:45	Levi & Korsinsky Reminds Gritstone bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS	accesswire.com
12:47	Gritstone bio, Inc. Class Action: Levi & Korsinsky Reminds Gritstone Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 – GRTS	globenewswire.com
11:15	Gritstone bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS	accesswire.com
11:00	GRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit	prnewswire.com
10:50	GRTS Investors Have Opportunity to Join Gritstone bio, Inc. Fraud Investigation with the Schall Law Firm	businesswire.com
10:45	GRTS LAWSUIT ALERT: Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	accesswire.com
05:45	Lost Money on Gritstone bio, Inc. (GRTS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm	prnewswire.com
05:45	Lost Money on Gritstone bio, Inc.(GRTS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm	prnewswire.com
05:30	Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Gritstone bio, Inc. (GRTS) Shareholders	accesswire.com
05:00	FINAL GRTS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Gritstone bio, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com
04:20	Gritstone bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GRTS	accesswire.com

Ideas & Opinions

Seeking Alpha 7 Apr 2024

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Seeking Alpha 3 Jan 2024

Gritstone bio: Looking For Validation In 2024
Seeking Alpha 14 Oct 2023

Gritstone bio: Renewed Excitement For Its COVID-19 Vaccine
Seeking Alpha 23 Apr 2023

Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point
Seeking Alpha 2 Jan 2023

Gritstone bio: Keep An Eye On This Discounted Cancer Vaccine Developer In 2023
Seeking Alpha 26 Sep 2022

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Seeking Alpha 5 Jul 2022

Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Seeking Alpha 14 Jun 2022

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Seeking Alpha 21 Apr 2022

Are Pan-Coronavirus Vaccines Possible?
Seeking Alpha 28 Nov 2021

Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Frequently Asked Questions (FAQ)

When is Gritstone bio's next earnings date?

Unfortunately, Gritstone bio's (GRTS) next earnings date is currently unknown.
Does Gritstone bio pay dividends?

No, Gritstone bio does not pay dividends.
How much money does Gritstone bio make?

Gritstone bio has a market capitalization of 3.80M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 85.64% to 1.33M US dollars.
What is Gritstone bio's stock symbol?

Gritstone bio, Inc. is traded on the NASDAQ under the ticker symbol "GRTS".
What is Gritstone bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Gritstone bio?

Shares of Gritstone bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Gritstone bio's key executives?
Gritstone bio's management team includes the following people:
- Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 58, pay: $873,680)
- Mr. Erin E. Jones M.S. Chief Operating Officer(age: 53, pay: $537,380)
Is Gritstone bio founder-led company?

Yes, Gritstone bio is a company led by its founder Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D..
How many employees does Gritstone bio have?

As Jul 2024, Gritstone bio employs 231 workers.
When Gritstone bio went public?

Gritstone bio, Inc. is publicly traded company for more then 6 years since IPO on 28 Sep 2018.
What is Gritstone bio's official website?

The official website for Gritstone bio is gritstonebio.com.
Where are Gritstone bio's headquarters?

Gritstone bio is headquartered at 5959 Horton Street, EmeryVille, CA.
How can i contact Gritstone bio?

Gritstone bio's mailing address is 5959 Horton Street, EmeryVille, CA and company can be reached via phone at +51 08716100.

Gritstone bio, Inc.

gritstonebio.com

Exchange:

NASDAQ

Full time employees:

231

Industry:

Biotechnology

Sector:

Healthcare

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

+51 08716100

5959 Horton Street
EmeryVille, CA 94608

CIK: 0001656634
ISIN: US39868T1051
CUSIP: 39868T105